Zobrazeno 1 - 10
of 1 286
pro vyhledávání: ''
Autor:
Isaac E. Kim, Monish Aron, Thomas L. Jang, Daniel D. Kim, Saum Ghodoussipour, Mark N. Stein, Isaac Yi Kim, David Y. Lee, Marc A. Dall'Era, Eric A. Singer, Sinae Kim
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 7909-7920 (2021)
Cancer Medicine
Cancer Medicine
Since 2004, multiple blockbuster drugs have been approved for men with metastatic prostate cancer. Nevertheless, it has been reported that no improvement in survival was observed between 2004 and 2009. Herein, we have analyzed the SEER database to as
Autor:
Yukio Naya, Kyokusin Hou, Satoko Kojima, Manato Kanesaka, Takahito Suyama, Hiroshi Masuda, Kazuhiro Araki, Ayumi Fujimoto
Publikováno v:
Anticancer Research. 41:4443-4446
BACKGROUND Androgen deprivation therapy (ADT) is one of the most effective treatments for advanced prostate cancer (PCa). However, it has been reported that the use of ADT is significantly associated with an increased risk of acute kidney injury (AKI
Autor:
Aasems Jacob, Riccardo Correa, Dileep Unnikrishnan, Zin W. Myint, P. V. Akhila Arya, Ghada Elshimy, Rishi Raj
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Objective We aimed to review of literature on the clinical presentation, management and outcomes of pituitary apoplexy following gonadotrophic release hormone (GnRH) agonist administration for the treatment of prostate cancer. Methods We used PRISMA
Autor:
Zhihui Liu, Michael A. Herman, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Geoffrey Liu
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 14, Pp 4814-4822 (2021)
Cancer Medicine, Vol 10, Iss 14, Pp 4814-4822 (2021)
Objectives Approximately 20% of patients diagnosed with non‐small cell lung cancer (NSCLC) have a history of prior (non‐lung) cancer. Patients with prior cancer are frequently excluded from clinical trials. We aimed to assess the potential impact
Autor:
Stefan Sleijfer, John W.M. Martens, Harmen J.G. van de Werken, Corine M. Beaufort, Anieta M. Sieuwerts, Job van Riet, Nikolas H. Stoecklein, Jaco Kraan, Yorick Sandberg, Peter A. W. te Boekhorst, Martijn P. Lolkema, Wytske M. van Weerden, Anouk C. de Jong, Paul Hamberg, S. Erkens-Schulze, Lisanne F. van Dessel, L. Mout, Thomas L.C. Woo, Ronald de Wit, Rui P L Neves
Publikováno v:
European Journal of Cancer, 150, 179-189. Elsevier Ltd.
Background: Circulating tumour cell (CTC)–derived organoids have the potential to provide a powerful tool for personalised cancer therapy but are restrained by low CTC numbers provided by blood samples. Here, we used diagnostic leukapheresis (DLA)
Autor:
Mari Bogaard, Kristina Totland Carm, Anne Cathrine Bakken, Marthe Løvf, Ulrika Axcrona, Karol Axcrona, Rolf Inge Skotheim, Susanne Gundersen Kidd, Linn Guro Olsen, Ragnhild A. Lothe
Publikováno v:
Neoplasia (New York, N.Y.)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 6, Pp 634-641 (2021)
Neoplasia: An International Journal for Oncology Research, Vol 23, Iss 6, Pp 634-641 (2021)
Highlights • The lncRNA SCHLAP1 predicts poor prognosis in multifocal primary prostate cancer • Expression of SCHLAP1 is heterogeneous within and between different malignant foci • Multiple samples per patient is crucial, otherwise high SCHLAP1
Autor:
L. Joseph Su, Steven E. Canfield, Mohit Khera, Yong Fang Kuo, Mary Peek, Konstantinos K. Tsilidis, David S. Lopez, Efstathia Polychronopoulou, Kyriakos S. Markides, Jay H. Fowke
Publikováno v:
Cancer Prev Res (Phila)
The associations of testosterone therapy (TTh) and statins use with prostate cancer remain conflicted. However, the joint effects of TTh and statins use on the incidence of prostate cancer, stage and grade at diagnosis, and prostate cancer-specific m
Autor:
Shaun Donovan, Russell Thomson, Joanne L. Dickinson, Janet L. Stanford, Georgea R. Foley, James R. Marthick, Liesel M. FitzGerald, Matthew A. Field, Roslyn C Malley, Annette Banks, Kelsie Raspin
Publikováno v:
International Journal of Cancer. 149:1089-1099
Prostate cancer (PrCa) is highly heritable, and although rare variants contribute significantly to PrCa risk, few have been identified to date. Herein, whole-genome sequencing was performed in a large PrCa family featuring multiple affected relatives
Publikováno v:
Cancer Medicine, Vol 10, Iss 5, Pp 1550-1561 (2021)
Cancer Medicine
Cancer Medicine
Background Older cancer survivors have high rates of long‐term opioid therapy (≥90 days/year). However, the geographical and temporal variation in long‐term opioid therapy rates for older cancer survivors is not known. Methods A retrospective c
Autor:
Alexander V. Louie, Liying Zhang, Patrick Cheung, Nauman Malik, Yee C. Ung, May Tsao, Georg A. Bjarnason, Ian Poon, Jeevin Shahi
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 109:764-774
Purpose Stereotactic body radiation therapy (SBRT) to metastatic mediastinal and hilar lymphadenopathy (MHL) is challenging owing to the proximity of centrally located organs-at-risk. As limited data exist on the safety and efficacy of SBRT for MHL,